SCHEDULE 13G: Intracoastal Capital and Affiliates Disclose 6.7% Passive Stake in Dermata Therapeutics

Intracoastal Capital LLC, along with Mitchell P. Kopin and Daniel B. Asher, has disclosed a passive beneficial ownership of 6.7% in Dermata Therapeutics, Inc., totaling 262,468 common shares.

Summary

• The filing is a Schedule 13G, indicating a passive investment purpose by the reporting persons.
• The reporting persons are Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC.
• The issuer is Dermata Therapeutics, Inc., with common stock (par value $0.0001 per share) as the class of securities.
• The CUSIP Number for the securities is 249845405.
• As of January 28, 2025, the reporting persons beneficially own an aggregate of 262,468 shares of Common Stock.
• This ownership represents approximately 6.7% of Dermata Therapeutics, Inc.'s Common Stock, based on 3,938,712 shares outstanding as of January 23, 2025.
• The reported beneficial ownership excludes shares issuable upon exercise of two warrants (Intracoastal Warrant 1 and Intracoastal Warrant 2) due to blocker provisions that prevent ownership from exceeding 4.99% and, for Warrant 1, require stockholder approval for exercise.
• Without these blocker provisions and assuming Intracoastal Warrant 1 was currently exercisable, the beneficial ownership would be 548,276 shares of Common Stock.

Sentiment

Score: 5

Explanation: The document is a factual regulatory filing (Schedule 13G) disclosing beneficial ownership, which inherently carries a neutral sentiment. It does not contain positive or negative operational or financial performance news.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: Disclosure of a significant passive stake by an investment group may influence market perception and trading activity.
• Company Management: Awareness of a new significant shareholder group.

Next Steps

• Stockholder approval is required for the exercise of Intracoastal Warrant 1 to exceed the 4.99% blocker provision, which would increase the beneficial ownership.

Key Dates

Keywords

Dermata Therapeutics, Intracoastal Capital, Mitchell P. Kopin, Daniel B. Asher, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Passive Investment, Therapeutics